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Combination chemotherapy in the management of early stage
small cell lung cancer (SCLC) is recognized as beneficial, despite
the low numbers of long-term cures achieved (Souhami and Law,
1990). Combination treatment yields a higher proportion of clin-
ically complete responses than single agent therapy, and two-year
survival rates of up to 30% have been reported from the use of
ifosfamide, carboplatin and etoposide (ICE) with thoracic radio-
therapy for patients with limited disease (Prendiville et al, 1994).
There is some evidence from randomized trials that the dose inten-
sity of treatment for SCLC may be important, with modest but
definite improvements in survival seen following the use of growth
factors to reduce the intervals between cycles of chemotherapy
(Steward et al, 1998). An alternative strategy for the intensification
of treatment is to use a cytoprotective agent to reduce normal
tissue toxicity, which might in turn allow dose escalation. 
Amifostine was originally identified as a radioprotective, but
has also proved to have chemoprotective properties (van der Vijgh
and Peters, 1994). The selectivity of its protective action in normal
tissues rather than tumours is based upon the much higher concen-
trations of active metabolites found in normal cells, owing to
differences in enzyme content (particularly alkaline phosphatases)
(Yuhas, 1980). Once reduced to the active form, the drug acts 
as a free-radical scavenger and impairs DNA adduct formation 
by a variety of cytotoxic agents. Apart from in vitro and animal
data confirming this action, there is data from a randomized 
trial in ovarian cancer in which patients received cisplatin and
cyclophosphamide with or without amifostine (Glick et al, 1992).
Those treated with amifostine experienced significantly less
neutropenia, required fewer admissions to hospital for manage-
ment of complications and were less likely to have treatment
stopped prematurely owing to renal impairment. There was no
difference in response rates or survival between the two arms. 
In the light of these observations, this study was conducted to test
the effect of amifostine in protecting against the myelosuppressive
effects of a modified ICE chemotherapy regimen in patients with
early small cell lung cancer. This regimen, comprising slightly atten-
uated doses of the cytotoxic drugs compared to the original study,
had been tested in a phase II trial previously by the Yorkshire
Thoracic Group (Shevlin et al, 1998). This had demonstrated a
response rate in keeping with other chemotherapy regimens (83%,
with 40% complete response) and a median survival among patients
with good prognosis disease of 12.6 months (95% CI = 11.6–14.7
months). Despite the reduced drug dosages however, haematologic
toxicities remained troublesome: 80% of patients experienced grade
III/IV neutropenia and 60% grade III/IV thrombocytopenia. The
purpose of the study was therefore to determine whether the delivery
of this treatment could be made less toxic by the co-administration of
a cytoprotective agent, with the intention of undertaking dose escala-
tion subsequently if this proved to be effective. 
MATERIALS AND METHODS 
Patient eligibility and randomization 
Patients were eligible for inclusion if they had microscopically
confirmed SCLC with either limited or extensive disease. Patients
with limited disease had WHO performance status 0 or 1, or 2 if both
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Patients with extensive disease were included if their performance
status was 0 or 1 and the sodium and alkaline phosphatase were
normal. An upper age limit of 75 years was set, and those with signifi-
cant renal impairment (creatinine > 150 µ mol 1–1),hepatic impair-
ment (bilirubin >50 µ mol l–1) or heart disease (NYHA grade III or
worse) were excluded. Radiological staging investigations
included chest X-ray and imaging of the abdomen by computed
tomography or ultrasound. Computed tomographic scans of the
brain, bone scintigraphy and marrow examinations were not
required in the absence of indicative symptoms, signs or blood
test abnormalities.
Following informed consent, patients were randomized 1:1 by
telephone stratified by treatment centre. They were allocated
treatment with either chemotherapy alone (C) or chemotherapy
preceded by amifostine (A). 
Treatment 
The chemotherapy comprised Carboplatin at a dose of 6 
(Glomerular filtration rate +25) mg given over 1 hour, Ifosfamide
3 g/m2 given as a 1 hour infusion with 3 g/m2 Mesna, and Etopo-
side 50mg b.d. orally for 7 days. Further Mesna was given following
the Ifosfamide infusion: 1.8 g/m2 was given by 8-hour intravenous
infusion on the first cycle and, if this was well tolerated, 1.2 g was
administered orally at 2 and 6 hours on subsequent cycles. Treatment
was scheduled to be repeated every 21 days to a maximum of 6
cycles. In the Amifostine arm the chemotherapy was identical, but
Amifostine 740 mg/m2 was administered as a 10-min intravenous
infusion immediately prior to the cytotoxics. Patients were treated
lying down and their blood pressure monitored carefully during
and after amifostine infusion in view of the known hypotensive
effects of the drug. The infusion was interrupted if the systolic
blood pressure dropped significantly or the patient became symp-
tomatic, and normal saline was administered at 20 ml min–1 until
recovery. Patients received routine anti-emetic prophylaxis with
5HT-3 antagonists and dexamethasone, and were prescribed oral
antibiotic prophylaxis to commence at day 8 of each cycle.
Patients did not receive haemopoietic growth factors. 
Nadir counts 
Following treatment the nadir blood count was measured at
day 10–12 of each cycle. A further blood count was performed at day
21–22 and treatment continued provided the absolute neutrophil
count was >2  109 l–1 and the platelet count >100  109 l–1. In
cases where the counts were lower than this, treatment was
delayed until recovery. In those cases where the nadir count
showed neutrophils <0.5  109 l–1 or platelets <25  109 l–1, or
where treatment was delayed due to incomplete recovery, all
subsequent cycles were administered with 25% reduction of the
doses of Ifosfamide and Carboplatin, and 6 days of oral etoposide
instead of 7. Patients requiring more than one dose modification
were withdrawn from the trial. Continuation with chemotherapy
treatment alone was permitted at the clinician’s discretion. 
Patients with limited disease were recommended to receive
consolidation thoracic radiotherapy 4 weeks after the last 
cycle of chemotherapy at a dose of 40 Gy in 15 fractions. No
recommendation was made concerning prophylactic cranial
irradiation. 
Assessments 
Patients were followed up for two years from the completion date of
chemotherapy or until death, whichever was sooner. Assessments
were made prior to each cycle of treatment, at one month from the
completion of treatment and 3 monthly thereafter. Tumour res-
ponses were assessed using standard WHO criteria (WHO, 1979).
Assessment of toxicity was carried out by the treating clinician prior
to each cycle of therapy and at the first follow-up visit. Patients
completed daily diary cards from the first day of chemotherapy until
4 weeks after the last cycle of treatment. The cards were based upon
those developed by the MRC Lung Cancer Working Party and
required patients to record their grade of nausea, vomiting, difficulty
in swallowing, activity, mood and overall condition using specified
scales. The cards were also used to record the taking of etoposide,
antiemetic and antibiotic medications. 
End points 
The primary outcome measure was haematologic toxicity, specifi-
cally the occurrence of grade III/IV neutropenia or thrombo-
cytopenia. Secondary endpoints were overall survival, response
rate, non-haematological toxicities and patient-reported symptoms
(i.e. nausea, vomiting, difficulty in swallowing, activity, mood and
overall condition as recorded in the daily diary cards). 
Sample size 
The study was designed to detect a 50% reduction of grade III/IV
neutropenia or thrombocytopenia, taking as the anticipated levels
the incidence of these in the previous phase II pilot study. Thus in
order to detect a reduction of neutropenia from 80% to 40% or of
thrombocytopenia from 60% to 30%, 84 patients were required for
80% power at the two-sided 5% significance level. 
Statistical analysis 
Analyses were conducted on an intention-to-treat basis for all
eligible randomized patients, except in the analyses of toxicity
data, where patients were analysed according to the treatments
they actually received. 
The maximum severities of neutropenia and thrombocytopenia
were calculated for each patient, over all cycles of treatment in the
trial, and the proportions experiencing at least one episode of
WHO grade III or IV toxicity were compared between the two
treatment groups using the χ 2 test at the 5% significance level. For
each toxicity proportion, the corresponding 95% confidence
interval was calculated. Where patients had missing data for toxi-
city, an additional analysis was performed assuming the worst case
scenario (i.e. WHO grade IV toxicity). Analyses were compared to
assess the potential impact of the missing data. 
Within each treatment group, all symptoms of non-haematolo-
gical toxicity were summarized independently as the number of
patients who experienced at least one episode of WHO grade III or
IV toxicity. 
The assessments of response were summarized, after each cycle
of chemotherapy, using the WHO criteria. The objective best
response achieved over all cycles of chemotherapy was docu-
mented for each treatment group. 
Survival was measured from the date of randomization until
death from any cause. Patients still alive at the time of analysis
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last recorded follow-up visit. Survival estimates were calculated
using the Kaplan-Meier method (Kaplan and Meier, 1958). 
The compliance of patients completing diary cards was calcu-
lated on a card basis, by dividing the number of completed diary
cards received by the number of diary cards expected. The
percentage of patient days when each grade of symptom was expe-
rienced was calculated for each cycle using the diary card record-
ings for the first 21 days following chemotherapy (i.e. the planned
length of the chemotherapy cycle). 
All analyses were performed using SAS software version 6.12. 
The protocol was approved by the local research ethical
committee of each participating centre. Written informed consent
was obtained from each patient before entry into the study. 
RESULTS 
84 patients (42 in each group) were randomized between
November 1996 and October 1998 from 16 Northern and
Yorkshire centres and 1 Southern centre. The two groups were
well matched at randomization for the known prognostic factors,
except for serum albumin where more patients in A had a level
below 35 g l–1 (Table 1). 
All the patients received treatment according to the randomiza-
tion, except for one. This patient was randomized to A but suffered
hypotension and was given the sixth cycle without amifostine due
to safety concerns. The total amount of chemotherapy given, on
study, was slightly lower in A, with 171 cycles in C and 141 cycles
in A. The dose intensity of the chemotherapy was the same in both
arms. Under the strict criteria for withdrawal following a second
episode of myelosuppression, 30 (71%) patients in C and 23 (55%)
patients in A were withdrawn from the study (Table 2). For the 30
patients in C, the median (range) number of chemotherapy cycles
received, on study, was 3 (2 to 6) and for the 23 patients in A, the
median (range) was 2 (2 to 6). Off study (i.e. after withdrawal for
myelosuppression), the median (range) number of chemotherapy
cycles received was 0.5 (0 to 4) for the patients in C and 1 (0 to 3)
for the patients in A. The medians after withdrawal excluded 4
patients in C and 5 patients in A, as it was unknown whether they
received further chemotherapy after follow-up. 
Amifostine infusions were interrupted or the total dose reduced
owing to side effects, principally hypotension, for some patients.
15 (36%) patients did not receive the full dose of amifostine on at
least one occasion, and of 141 infusions given, 27 (19%) were at a
reduced rate. 
There was no statistically significant difference between the two
arms in terms of the neutropenia or thrombocytopenia observed
(Table 3). The overall incidence of at least one episode of grade III
or IV neutropenia during treatment was 78% in C and 71% in A,
and at least one episode of grade III or IV thrombocytopenia was
14% in C and 26% in A. When missing data was treated as the
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Figure 1: Overall survival for the randomized treatment arms 
(Kaplan-Meier estimates)
Table 1 Characteristics of randomized patients 
ICE (C) ICE + 
amifostine (A) 
Number of patients randomized 42 42 
Males: Females 24:18 28:14 
Median age (range) in years 64 (45–75) 65 (43–74) 
WHO performance status: 
0 16 (38%) 20 (48%) 
1 24 (57%) 21 (50%) 
2 2 (5%) 1 (2%) 
Disease extent: 
Limited 35 (83%) 34 (81%) 
Extensive 7 (17%) 8 (19%) 
Presence of metastases: 
Present 6 (15%) 8 (19%) 
Absent 35 (85%) 34 (81%) 
Missing 1 0 
Biochemistry at randomization:
Sodium <135 7 (18%) 8 (19%) 
(mmol/l) ≥ 135 33 (83%) 34 (81%) 
Missinga 20  
Albumin <35 3 (8%) 6 (15%) 
(g/l) ≥ 35 37 (92%) 35 (85%) 
Missinga 21  
Alkaline phosphate < 300 37 (93%) 39 (95%) 
(iu/l) ≥ 300 3 (7%) 2 (5%) 
Missinga 21  
LDH <450 13 (46%) 7 (32%) 
(iu/l) ≥ 450 15 (54%) 15 (68%) 
Missinga 14 20 
NSE <12.5 4 (17%) 7 (32%) 
≥ 12.5 20 (83%) 15 (68%) 
Missinga 18 20 
aThese results cannot be retrieved as they were not done at the time of blood
assay. 
Table 2 Reasons for withdrawals 
ICE (C) ICE + amifostine (A)
(n = 42) (n = 42) 
Number of withdrawals 33 (79%) 35 (83%) 
Reasons for withdrawala
Evidence of tumour progression 0 4 (10%) 
Failure to respond after 2 cycles 0 1 (2%) 
Myelosuppression requiring second  30 (71%) 23 (55%) 
25% dose reduction
Serious allergic reaction to amifostine 0 1 (2%) 
Patient develops need for palliative 1 (2%) 0 
radiotherapy
Patient desires to be withdrawn 2 (5%) 7 (17%) 
Other reasonsb 1 (2%) 3 (7%) 
aPossible to have more than one reason for withdrawal. bOther reasons: ICE
arm: Toxicity – severe paresthesia one side of body (may be stroke related);
ICE + amifostine arm: Refused amifostine due to vomiting when first
administered, Congestive cardiac failure and arterial fibrilation, Severe
anaemia. worst case scenario (i.e. WHO toxicity grade IV) there was no
statistically significant difference between the two groups. Examin-
ing only cycle 1, to eliminate the potential confounding effects of
dose reductions and withdrawals, shows a similar picture: 57% in
C and 50% in A experienced grade III or IV neutropenia. There is
some suggestion of an effect upon grade III or IV thrombo-
cytopenia: in C the incidence was 5% and in A 17%. 
There was no difference in the number of infectious episodes,
bleeding, platelet transfusions or red blood cell transfusions
between the two arms. 
The non-haematologic toxicity, such as alopecia, gastroin-
testinal toxicity, renal impairment and neurotoxicity were equally
common in both arms. However, grade III/IV nausea and vomiting
showed a slight excess in the C arm: this occurred in 12 of 42
(29%) C patients compared to 3 of 42 (7%) A patients (95% CI for
difference = 6% to 38%). 
The objective best response rates were similar in both arms.
Overall there were 38 patients (90%) in each arm who showed a
complete or partial response at some point during their treatment. 
In total 56 patients died: 29 in C and 27 in A. The overall
survival was similar, however the median overall survival time
was slightly higher in A: 14 months in A and 11 months in C
(Figure 1). At 12 months since randomization overall survival in
C was 42% and in A 60% (95% CI for difference =  3% to 39%). 
The diary cards were effective as a means of gathering subjec-
tive toxic events to treatment. 74% of cards were returned, equally
distributed between the two treatments, with good completion of
the data items requested. The symptoms reported were similar,
except for nausea and vomiting which showed a trend towards
lesser severity in A, and overall condition which was rated higher
in A, particularly following the second and subsequent cycles
(Table 4). The effects of withdrawals were examined and it was
found that these did not cause the estimates to be biased. 
DISCUSSION 
The 90% objective response rate and median one-year overall
survival in this study confirm the activity of the attenuated ICE
regimen against small cell lung cancer of relatively favourable
prognosis. These figures compare well with those reported from
other recent trials of combination chemotherapy (Roth et al, 1992;
Miles et al, 1994), although clearly a randomized study would be
required to confirm the therapeutic equivalence of the lower dose
regimen. Recent evidence suggests that small gains in survival
may be achieved with intensification of the ACE regimen using
growth factors to shorten the cycle length, and this benefit only
became apparent when more than half the patients had died and
comparison was made of the long survival groups (Thatcher et al,
2000). It would therefore be premature to conclude that the attenu-
ated ICE regimen used in this study is truly as effective as more
intensive chemotherapy, and further studies will be necessary to
examine this. 
This study has demonstrated the feasibility of administering a
cytoprotective agent together with chemotherapy, although the full
dose could not be given in all patients owing to toxicity. The use of
amifostine does not appear to confer any protection upon the
tumour itself. This was an important theoretical concern for such
studies, particularly in the setting of SCLC where acquired
chemoresistance is common. Although there was a small excess of
early treatment failure in A, the cycle-by-cycle response rates in the
two arms were comparable through the treatment, with no sugges-
tion that responses in A rose after withdrawal from the study. Most
importantly the overall survival was similar. Another concern
regarding the use of amifostine was the possibility of increased side
effects such as nausea and vomiting. In practice this was not prob-
lematic in A, and indeed there was a trend towards less nausea and
vomiting. It is not clear why this should have been the case: the use
of 5-HT3 blocker anti-emetics was standardized in both arms and
no difference was recorded in the adherence to the protocol in this
respect. The finding of better scores for overall condition on the
diary cards in A was unexpected given previously documented
toxicity profile of the drug, but it is reassuring to know that it did
not have any detrimental effect from the perspective of the patient.
The slight excess of withdrawals at the request of patients in A
(17% compared to 5%) was not apparently related to the side-
effects of the amifostine. No calculation of statistical significance
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Table 3 Proportion of patients experiencing at least one episode of WHO
grade III or IV neutropenia and/or thrombocytopenia 
ICE  ICE + amifostinea Test statistic,
(C) (A) df P value 
Number of patients randomized 42 42b  
Grade III or IV neutropenia  33 (78%) 30 (71%) χ 2 = 0.675, 
(%) df = 1 
95% C.I. (66 91%) (58, 85%) P = 0.411 
Grade III or IV thrombo- 6 (14%) 11 (26%)  χ 2 = 2.004, 
cytopenia (%) df = 1
95% C.I. (4, 25%) (13, 40%) P = 0.157 
Grade III or IV neutropenia and/
or thrombocytopenia (%) 33 (78%) 30 (71%) – 
95% C.I. (66, 91%) (58, 85%) – 
95% CI = 95% Confidence interval for the proportion of patients with WHO
grade 3 or 4 toxicity. aChi-square test statistic, df, P-values quoted are
unadjusted. b42 patients randomized to ICE and amifostine, but one patient
did not receive amifostine for their last cycle. This patient had already
experienced grade 3/4 toxicity before cycle 6. 
Table 4 Patient reported toxicity (percentage of patient days when
moderate/severe grade of symptom was experienced) 
Cycle 1 Cycle 2 Cycle 3 Cycle 4 Cycle 5 Cycle 6 
Nausea C 3.5% 3.4% 1.8% 1.2% 4.8% 4.8%
Grades 3 & 4 A 3.0% 1.8% 2.4% 2.1% 1.6% 0.8% 
Vomiting C 2.4% 1.2% 1.0% 0.7% 0.3% 0
Grades 3 & 4 A 0.9% 0.6% 0.6% 1.0% 0.8% 1.6% 
Swallowing C 2.4% 0.9% 0 0 0.5% 1.0%
Grades 3, 4 & 5 A 2.9% 0.3% 0 0.3% 0  0 
Activity C 8.0% 5.5% 7.1% 6.6% 5.0% 1.9%
Grades 4 & 5 A 13.6% 8.0% 11.3% 11.0% 11.9% 2.4% 
Mood C 5.7% 3.4% 5.5% 4.7% 5.0% 3.1%
Grades 4 & 5 A 5.9% 4.1% 4.4% 5.3% 3.2% 1.6% 
Overall C 5.8% 3.2% 5.8% 4.3% 4.8% 4.1%
Grades 4 & 5 A 7.0% 2.6% 2.5% 0.8% 0.8% 1.6% 
C = ICE alone; A = ICE + amifostine; Nausea grades 3 & 4 = moderate /
severe; Vomiting grades 3 & 4 = sick 2 or more times per day; Swallowing
grades 3, 4 & 5 = can swallow solids with difficulty / can’t swallow solids /
can’t swallow liquids; Activity grades 4 & 5 = confined to home or hospital /
confined to bed; Mood grades 4 & 5 = miserable / very miserable; Overall
grades 4 & 5 = poor / very ill has been made for this data since this was not specified as a primary
endpoint and is a post-hoc summary based on inspection of data. A
post-hoc analysis is therefore liable to over-interpretation. 
The principal end-point of the study was haematologic toxicity,
and amifostine as used here does not appear to have exerted a
significant effect, there is a slight increase in thrombocytopenia
after the first cycle. Randomized studies of supportive therapy are
complex to interpret over a prolonged course of treatment owing to
the potential confounding effects of dose reductions and with-
drawal of patients with excessive toxicity, and in this respect the
data from the first cycle is the most reliable. However use of strict
withdrawal criteria was a means to give a further indication of the
comparative degree of myelosuppression as it might be relevant in
practice, and here there was a trend in favour of the A arm. 
Several reasons can be put forward to explain the lack of effect
by amifostine in this trial compared to previous randomized
studies which have demonstrated a reduction of myelosuppression.
The chemotherapy used in this protocol may be less amenable to
the cytoprotective effect of amifostine, and in particular the
prolonged administration of oral etoposide is a likely confounding
factor. The etoposide can be expected to exert a myelotoxic effect
for considerably longer than the duration of action of the amifos-
tine, which has an α half life of less than 1 minute and β half-life
of 9.5 minutes in serum, although the intracellular effect is likely
to be much more prolonged (Yuhas, 1980). In designing the study
it was anticipated that if there was a significant effect upon the
toxicity produced by ifosfamide and carboplatin administered
immediately after the amifostine this might result in less overall
myelosuppression. However it is possible that the dominant effect
upon the bone marrow is exerted by the etoposide for which the
amifostine was not effective. Given the schedule dependency of
the therapeutic effect of etoposide which has been demonstrated in
SCLC, it is important that this is administered over at least 72
hours, and it would not be practical to co-administer amifostine for
the full duration of drug exposure. 
Another consideration is the use of 740 mg/m2 rather than the
more commonly used 910 mg/m2 dose of amifostine in this study.
Previous studies have not indicated a significantly different effect
at the higher dose level in terms of cytoprotection, and a small
crossover trial of cyclophosphamide used with or without amifos-
tine given in a single dose of 740 mg/m2 showed a significant
reduction in depth and duration of neutropenia (Glover et al,
1986). There was a suggestion from previous work with amifos-
tine that toxicity was greater at the higher dose, and in the present
study there was a significant incidence of side-effects even at 740
mg/m2, with reductions of the total dose administered in 36% of
patients for this reason. Whilst it is possible that a higher
prescribed dose might have exerted a greater cytoprotective effect,
it is also likely that more dose reductions would have been
required. 
A further factor to consider is whether the chemotherapy was
sufficiently myelosuppressive to demonstrate an effect from cyto-
protection. Whilst the doses are less than those of the original ICE
regimen, a 75% incidence of grade III or IV neutropenia is signifi-
cant and in keeping with that seen in the previous study of the
attenuated ICE regimen. The level of myelosuppression is similar
to that seen in the trials of cyclophosphamide and cisplatin for
ovarian cancer where a positive effect was demonstrated from the
use of amifostine (Glick et al, 1992). 
In conclusion, this study has shown that amifostine can be admin-
istered safely in combination with modified ICE chemotherapy for
SCLC, but that it had no appreciable effect upon the degree of
myelosuppression or other toxicities. The contrast with previous
studies in which a cytoprotective effect has been shown is most
likely to be due to the use of etoposide over a prolonged period. If
amifostine is to be used for the attenuation of myelotoxicity in
SCLC it will need to be given with drugs all of whose half-life is
sufficiently short for the cytoprotective effect to persist for the
duration of cytotoxic action. In practice, the use of haemopoietic
growth factors may provide a more reliable means to limit
neutropenia, and for this reason they are likely to be preferred
in the supportive therapy of patients with SCLC undergoing
chemotherapy. 
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